CompletedPhase 4

Rituximab and RASi in Patients with IgAN

China116 participantsStarted 2020-07-01

Plain-language summary

A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. 24h proteinuria ≥1g;
✓. Bp\<130/80 mmHg；
✓. ) intradermal augmentation ( E1 ),
✓. ) crescentic body 0 - 50 % ( C1 / C2 ),
✓. ) fibrinoid necrosis,
✓. ) more interstitial inflammatory cell infiltration. At the same time, the proportion of sclerosis was low ( spherical or segmental sclerosis ball \< 50 % ), and interstitial fibrosis was low ( below T2 ).

Changes in proteinuria levels over 1 year compared with baseline

Timeframe: 1 year

NCT IDNCT04525729

SponsorNan Chen,MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03-30